Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dasatinib + Lapatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 29 BTK inhibitor 33 CSF1R Inhibitor 28 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 55 PDGFR Inhibitor (Pan) 28 SRC Inhibitor 31 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|Lapatinib||Tykerb||Lapatinib Ditosylate||EGFR Inhibitor (Pan) 57 HER2 Inhibitor 39||Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|